Overview: JC Virus RNA TestIntroduction: The JC Virus RNA Test detects JC virus RNA to confirm active infection, aiding in diagnosis of progressive multifocal leukoencephalopathy in immunocompromised patients. Affecting 1 in 100,000 immunocompromised individuals, PML poses diagnostic challenges due to rapid progression. Following 2023 Centers for Disease Control and Prevention (CDC) guidelines, it uses RT-PCR for high sensitivity, supporting virology screening. This test is vital for diagnosis, treatment planning, and improving outcomes in neurology.
Other Names: JC Virus RNA Test, Active PML RNA Assay.
FDA Status: Laboratory-developed test (LDT), meeting virology standards for diagnostic reliability.
Historical Milestone: JC virus RNA testing began in the 2000s with research by White, who developed RT-PCR methods. RT-PCR advancements by Roche improved detection, surpassing earlier DNA-based PCR.
Purpose: Detects JC virus RNA to confirm active infection, guides supportive care, and evaluates patients with neurological decline, aiming to manage disease.
Test Parameters: JC virus RNA presence
Pretest Condition: No special preparation required. Collect CSF or whole blood. Report history of immunosuppression.
Specimen: CSF (sterile container, 1-2 mL), Whole Blood (EDTA, 3-5 mL); 1 mL CSF or 2 mL serum in sterile container. Transport in a biohazard container.
Sample Stability at Room Temperature: 6 hours
Sample Stability at Refrigeration: 1 week
Sample Stability at Frozen: 1 month
Medical History: Document neurological decline or immunosuppression. Include current medications or HIV status.
Consent: Written consent required, detailing the test's purpose, disease risks (e.g., brain damage), and sample collection risks.
Procedural Considerations: Uses RT-PCR to detect RNA, requiring labs with thermal cyclers. Results available in 3-5 days. Performed in labs with strict handling.
Factors Affecting Result Accuracy: Sample degradation or contamination can affect results. Medications may not affect results but require correlation.
Clinical Significance: Positive RNA confirms active PML, guiding care. Early management might slow progression, while untreated cases lead to death. Negative results may require MRI.
Specialist Consultation: Consult a neurologist or infectious disease specialist for interpretation.
Additional Supporting Tests: MRI, JC virus PCR, or immune status to confirm diagnosis.
Test Limitations: Specific to active infection; correlation with imaging needed. False negatives possible with low viral load.
References: CDC Guidelines, 2023; Journal of Clinical Microbiology, White FA, 2022.
